Galectin Therapeutics (GALT) sinks 39% as trading resumes

September 27, 2016 4:47 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Galectin Therapeutics (NASDAQ: GALT) sinks 39% as trading resumes after a recent trial failed.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk, Trading Halts

Add Your Comment